SCHEMBL25969253

SCHEMBL25969253

O=C(O)c1nn(CCC(F)(F)F)c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
PMP22 Q01453 1/20 0.50
HIF1A Q16665 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CNR1 P21554 2/20 0.46
CNR2 P34972 2/20 0.46
PTGER4 P35408 5/20 0.45
HTR3A P46098 4/20 0.45
F2 P00734 1/20 0.44
PLAU P00749 1/20 0.44
ELANE P08246 1/20 0.44
KDM4C Q9H3R0 3/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4050608 0.91 CNR1 (0.52) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL29805363 0.85 HTR3A (0.55) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL29805307 0.84 ELANE (0.52) CNR1CNR2PTGER4HTR3AF2
SCHEMBL19127321 0.82 KDM4C (0.51) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL31429522 0.82 TSHR (0.54) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5438502 0.82 TSHR (0.54) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7908910 0.82 HTR3A (0.42) CNR1CNR2PTGER4HTR3AF2
SCHEMBL3017718 0.81 TSHR (0.53) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL15897852 0.79 TSHR (0.52) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL28985448 0.79 CNR1 (0.66) TSHRCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE METREA BIOSCIENCES INC (US) 2025-03-20 US disclosed
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
WO-2022159445-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE METREA BIOSCIENCES, INC. (US) 2022-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 TSHR 4477/4885CYP1A2 4727/4885CYP3A4 4787/4885
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE LPL, LIPA, PNLIP TSHR 1493/4885CYP1A2 973/4885CYP3A4 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.